Alterity Therapeutics is a development stage enterprise engaged in the research and development of therapeutic drugs designed to treat the underlying cause of degeneration of the brain focusing on Alzheimer's disease, Huntington disease, Parkinson's disease and other neurological disorders. Co. is developing therapies to treat neurodegenerative diseases. Co.'s primary drug candidate, ATH434 is for treatment of Parkinson's disease. Other applications for Co.'s main compounds include the treatment or amelioration of neurodegenerative disorders such as tauopathies, Motor Neuron disease, Creutzfeldt-Jakob disease, certain cancers, age-related macular degeneration, or antibiotic resistance. We show 1 historical shares outstanding datapoints in our coverage of ATHE's shares outstanding history.
Understanding the changing numbers of ATHE shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ATHE versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ATHE by allowing them to research ATHE shares outstanding history
as well as any other stock in our coverage universe. |
Free ATHE Email Alerts:
Video: Shares Outstanding Importance
